A study in a rat initiation-promotion bladder tumour model demonstrated no promoter/progressor potential of dapagliflozin
In conclusion, dapagliflozin does not act as promoter or progressor of bladder cancer in a validated bladder cancer model in rats.
Source: Regulatory Toxicology and Pharmacology - Category: Toxicology Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Carcinoma | Dapagliflozin | Diabetes | Diabetes Type 2 | Diets | Drugs & Pharmacology | Endocrinology | Forxiga | Nutrition | SGLT2 Inhibitors | Sodium | Study | Toxicology | Transitional Cell Carcinoma